[近期在诊断和治疗Ph(+) 多血统性急性淋巴细胞白血病方面的进展]
1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China.
费城染色体阳性急性淋巴细胞白血病 (Ph(+) ALL) 涉及多个血统,由于持续的BCR::ABL1阳性,因此存在诊断挑战. 本综述探讨了其特征和对更好的治疗策略的临床影响.
科学领域:
- 血液学
- 癌症学
- 分子生物学
背景情况:
- 费城染色体阳性急性淋巴细胞白血病 (Ph(+) 的分层治疗依赖于分子标志物和MRD监测.
- 随着先进的治疗和检测方法的使用,MRD评估的差异,特别是持久的BCR:ABL1阳性,越来越多.
研究的目的:
- 检查多系 ALL 的分子和病理特征.
- 讨论潜在的预后生物标志物,疾病演变模式和临床影响.
- 为改善这种特定亚型的诊断和治疗策略提供信息.
主要方法:
- 对分子和病理学研究的综合文献综述.
- 分析目前的MRD评估技术及其局限性.
- 综合有关疾病演变和临床结果的数据.
主要成果:
- 持续的BCR:ABL1阳性可能表明多个血系细胞参与,而不仅仅是残留的淋巴细胞.
- 具有多个血统参与的ALL缺乏标准化的诊断标准和预后框架.
- 这种亚型对临床决策提出了独特的挑战.
结论:
- 对于准确诊断至关重要的是了解多个血统参与的Ph(+) ALL.
- 需要进一步研究以建立标准化标准和预后标记.
- 需要量身定制的治疗策略来解决这种独特的生物特征.
更多相关视频
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
相关概念视频
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...